- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Immune dysregulation.
Displaying page 1 of 1.
EudraCT Number: 2020-001039-29 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-01 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL | |||||||||||||
Medical condition: Organ dysfunction by the novel SARS-Cov-2 virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005827-35 | Sponsor Protocol Number: RC31/20/0441 | Start Date*: 2021-03-25 |
Sponsor Name:University Hospital of Toulouse | ||
Full Title: SARS-CoV-2 neurotropism, micRoglial ActivatioN and cytokine dySregulaTiOn in COVID-19 patients with delirium | ||
Medical condition: delirium | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000515-24 | Sponsor Protocol Number: NL76470.078.21 | Start Date*: 2021-02-15 | |||||||||||
Sponsor Name:Erasmus University Medical Center | |||||||||||||
Full Title: Vaccination Against Covid in Primary Immune Deficiencies | |||||||||||||
Medical condition: Patients with primary immunodeficiency disease, also known as inborn errors pf immunity, are vaccinated against COVID-19 using COVID-19 Vaccine Moderna. The vaccine has been approved for use in the... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003369-27 | Sponsor Protocol Number: REGAIN | Start Date*: 2016-07-01 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | ||||||||||||||||||
Full Title: A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID) | ||||||||||||||||||
Medical condition: autoimmune enteropathy (AIE) in common variable immunodeficiency (CVID). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004003-46 | Sponsor Protocol Number: RealMM | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITĂ€ DI TORINO | |||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT... | |||||||||||||
Medical condition: Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005570-12 | Sponsor Protocol Number: RCSI SR&D 09/08/07 | Start Date*: 2008-11-14 | |||||||||||
Sponsor Name:Geistlich Pharma AG | |||||||||||||
Full Title: Protocol Title: A multicentre, randomised placebo controlled, parallel group clinical trial to evaluate the anti-neoplastic effects of Taurolidine in patients undergoing curative surgery for non-m... | |||||||||||||
Medical condition: Patients of both genders between 18 - 85 years of age undergoing elective surgery for a histologically confirmed solitary, non-metastatic colonic tumour and not including rectal tumours within 15cm... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
